Bafna Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.
Growth
Compounded Sales Growth
10 Years:
-1%
5 Years:
28%
3 Years:
29%
TTM:
2%
Compounded Profit Growth
10 Years:
18%
5 Years:
19%
3 Years:
8%
TTM:
-96%
Stock Price CAGR
10 Years:
10%
5 Years:
88%
3 Years:
-13%
1 Year:
-9%
Return on Equity
10 Years:
-17%
5 Years:
10%
3 Years:
13%
Last Year:
9%
Last Updated: Unknown
Balance Sheet
Last Updated: September 15, 2024, 4:01 pm
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Equity Capital
19
19
19
19
19
24
24
2
24
24
24
24
Reserves
49
50
53
41
22
17
-3
49
33
38
50
57
Borrowings
91
99
64
80
82
47
46
3
15
11
23
24
Other Liabilities
84
54
50
45
44
40
54
17
14
17
33
42
Total Liabilities
243
223
185
185
167
128
121
71
86
90
130
148
Fixed Assets
66
63
49
47
43
40
37
35
36
39
40
40
CWIP
0
0
0
0
0
0
0
0
1
0
2
12
Investments
1
1
18
18
18
1
1
0
0
0
0
0
Other Assets
175
158
118
120
106
86
82
36
50
51
88
95
Total Assets
243
223
185
185
167
128
121
71
86
90
130
148
Reserves and Borrowings Chart
Cash Flow
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Cash from Operating Activity
35
1
9
-3
14
-7
-1
-34
-14
10
5
9
Cash from Investing Activity
-6
-5
56
-1
-8
38
4
33
-5
-7
-7
-15
Cash from Financing Activity
-11
-14
-66
4
-5
-31
-2
7
12
-5
10
-1
Net Cash Flow
18
-18
-0
0
-0
0
0
6
-7
-2
8
-6
Free Cash Flow
Month
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Free Cash Flow
18.00
-70.00
-78.00
-80.00
-77.00
-87.00
-82.00
-59.00
-2.00
-5.00
1.00
-7.00
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Free Cash Flow Chart
Financial Efficiency Indicators
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Debtor Days
187
192
303
291
302
195
208
52
49
63
130
109
Inventory Days
63
78
66
92
118
102
122
208
154
185
129
125
Days Payable
215
116
149
169
164
265
517
229
107
113
165
149
Cash Conversion Cycle
35
155
220
214
255
31
-188
31
96
135
94
84
Working Capital Days
150
204
250
320
207
79
-16
89
172
148
150
126
ROCE %
9%
9%
-13%
-0%
-6%
-36%
-21%
-3%
10%
11%
16%
9%
Financial Efficiency Indicators Chart
Share Holding Pattern
Month
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Promoters
90.40%
90.42%
90.42%
90.12%
90.00%
90.01%
89.99%
89.99%
88.73%
88.42%
88.29%
88.29%
Public
9.60%
9.58%
9.58%
9.88%
10.00%
9.98%
10.00%
10.00%
11.27%
11.57%
11.70%
11.71%
No. of Shareholders
8,068
7,910
7,326
7,223
7,275
7,199
7,120
6,992
7,354
7,367
7,539
7,391
Shareholding Pattern Chart
No. of Shareholders
This stock is not held by any mutual fund
ROCE Trend
EPS Trend
Key Financial Ratios
Month
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
FaceValue
10.00
10.00
10.00
10.00
10.00
Basic EPS (Rs.)
-15.52
-11.48
-7.15
-10.43
-8.80
Diluted EPS (Rs.)
-15.52
-11.48
-7.15
-10.43
-8.80
Cash EPS (Rs.)
-89.52
-6.29
-5.47
-8.17
-5.51
Book Value[Excl.RevalReserv]/Share (Rs.)
-17.59
7.97
15.73
22.57
30.95
Book Value[Incl.RevalReserv]/Share (Rs.)
-17.59
7.97
15.73
22.57
30.95
Revenue From Operations / Share (Rs.)
179.54
18.33
19.94
34.82
45.73
PBDIT / Share (Rs.)
6.25
-5.36
-1.61
-2.50
1.34
PBIT / Share (Rs.)
-7.56
-6.83
-3.29
-4.76
-1.27
PBT / Share (Rs.)
-103.32
-7.30
-6.22
-10.91
-8.21
Net Profit / Share (Rs.)
-103.32
-7.76
-7.15
-10.43
-8.12
NP After MI And SOA / Share (Rs.)
-104.54
-7.98
-7.07
-10.23
-7.52
PBDIT Margin (%)
3.48
-29.26
-8.05
-7.18
2.92
PBIT Margin (%)
-4.20
-37.28
-16.47
-13.68
-2.76
PBT Margin (%)
-57.54
-39.86
-31.19
-31.34
-17.95
Net Profit Margin (%)
-57.54
-42.32
-35.84
-29.95
-17.74
NP After MI And SOA Margin (%)
-58.22
-43.52
-35.48
-29.38
-16.44
Return on Networth / Equity (%)
0.00
-99.01
-44.12
-44.73
-24.28
Return on Capital Employeed (%)
-3.29
-33.22
-9.90
-9.17
-2.41
Return On Assets (%)
-34.67
-15.79
-12.09
-10.70
-7.27
Long Term Debt / Equity (X)
-0.71
1.21
0.61
0.91
0.60
Total Debt / Equity (X)
-0.71
2.43
1.23
1.93
1.39
Asset Turnover Ratio (%)
0.44
0.33
0.30
0.36
0.44
Current Ratio (X)
2.11
0.68
0.81
0.94
1.29
Quick Ratio (X)
1.44
0.55
0.63
0.74
1.11
Inventory Turnover Ratio (X)
2.24
2.66
1.55
0.89
0.97
Interest Coverage Ratio (X)
15.48
-5.97
-0.54
-0.40
0.19
Interest Coverage Ratio (Post Tax) (X)
-18.72
-8.10
-1.44
-0.69
-0.16
Enterprise Value (Cr.)
-3.29
69.21
109.10
134.30
133.55
EV / Net Operating Revenue (X)
-0.07
1.60
2.31
2.07
1.57
EV / EBITDA (X)
-2.22
-5.45
-28.71
-28.76
53.52
MarketCap / Net Operating Revenue (X)
0.04
0.59
1.40
0.84
0.65
Price / BV (X)
-0.49
1.36
1.75
1.29
0.96
Price / Net Operating Revenue (X)
0.04
0.59
1.40
0.84
0.65
EarningsYield
-11.80
-0.72
-0.25
-0.34
-0.25
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Bafna Pharmaceuticals Ltd as of October 5, 2024 is: ₹1,080.12
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of October 5, 2024, Bafna Pharmaceuticals Ltd is Undervalued by 1,193.56% compared to the current share price ₹83.50
Intrinsic Value of Bafna Pharmaceuticals Ltd as of October 5, 2024 is: ₹2,776.77
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of October 5, 2024, Bafna Pharmaceuticals Ltd is Undervalued by 3,225.47% compared to the current share price ₹83.50
Last 5 Year EPS CAGR: 157.08%
*Investments are subject to market risks
Strength and Weakness
Strength
Weakness
The stock has a low average ROCE of -1.25%, which may not be favorable.
The stock has a high average Working Capital Days of 156.58, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 96.83, which may not be favorable.
The company has higher borrowings (48.75) compared to reserves (38.00), which may suggest financial risk.
The company has not shown consistent growth in sales (98.00) and profit (-2.77).
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bafna Pharmaceuticals Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 0% (Industry Average ROE: 16%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 317 (Industry average Stock P/E: 62.97)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: -0.71
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Bafna Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 28/03/1995 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24294TN1995PLC030698 and registration number is 030698. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 85.14 Cr. and Equity Capital is Rs. 23.66 Cr. for the Year ended 31/03/2022.
INDUSTRY
ADDRESS
CONTACT
Pharmaceuticals
Bafna Towers, New�No.�68,�Old�No. 299,�� � Chennai (Madras) Tamil Nadu 600001
Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bafna Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Manage Consent
We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
